
Guardant Health (NASDAQ:GH) expects expanded insurance coverage for its Shield screening test and continued growth in its cancer testing portfolio to support its business in 2027, while maintaining a target of reaching free cash flow break-even in the fourth quarter of that year.
Speaking at a company news event, Co-CEO Helmy Eltoukhy said Guardant360, the company’s late-stage cancer therapy selection test, recorded nearly 30% volume growth in the third quarter. Guardant Reveal, its test for minimal residual disease, grew more than 100% year over year, while Shield volumes roughly tripled, he said.
Shield coverage and spending plans
Co-CEO and President AmirAli Talasaz said Shield has about 100 million covered lives, and interviewer Tycho Peterson cited 83,000 tests in the third quarter. Talasaz said recent reimbursement wins could increase ordering among younger patients and at existing physician accounts.
Talasaz described the coverage expansion as a “2027 volume boost story.” UnitedHealthcare coverage began in August, Carelon coverage took effect recently, and other coverage is due to become effective in January, he said.
CFO Michael Bell said Guardant has begun receiving payments from UnitedHealthcare, but payments can vary while the company is out of network. He expects it will take time to establish consistent payment histories and contracts with insurers. Guardant could begin accruing commercial revenue and seeing the revenue impact in the second half of 2027, he said.
Guardant plans to continue expanding its Shield sales force from more than 400 representatives toward a steady-state level of 600 to 700, Talasaz said. The company also intends to increase direct-to-consumer marketing after pilot results exceeded its expectations. Some additional gross profit next year will be reinvested in those efforts, he said.
Talasaz said a U.S. Preventive Services Task Force recommendation remains an important potential catalyst for broader access without out-of-pocket costs, although he said Guardant has room to grow while awaiting a recommendation.
Testing portfolio and costs
Eltoukhy said the expected full launch of the FDA-approved Guardant360 Liquid CDx next year could help drive volume growth. Guardant also recently launched 11 new Smart Apps on the platform, including applications intended to help predict responses to immune checkpoint inhibitors and characterize PD-L1 in blood, he said.
The company has submitted its Guardant360 Tissue test for FDA approval and hopes to receive a decision next year, Eltoukhy said. He also cited increased breast cancer testing following the approval of ETCAMAH, while noting that serial testing is still at an early stage.
For minimal residual disease testing, Eltoukhy said Guardant plans to serve both tissue-free and tumor-informed use cases through Guardant Reveal and Guardant Reveal Ultra. The company is running thousands of samples and developing clinical validity studies across major tumor types, he said.
Bell said Shield’s cost per test fell from more than $400 at the start of the third quarter to $330 during the quarter, following the introduction of a lower-cost, higher-throughput version. Guardant is targeting a cost of $200 per test by the end of 2028. Additional automation will require FDA approval, which the company expects around late 2027, he said.
Cash flow outlook
Bell said Guardant remains on track for free cash flow break-even in the fourth quarter of 2027. The business excluding screening reached break-even last year and is generating positive cash flow this year, he said. Screening cash burn is expected to decline in the second half of 2027 as the business gains scale.
Bell said the company’s target did not assume Advanced Diagnostic Laboratory Test status for Guardant360. He described that designation as potential upside and said the company’s base case is for it to take effect April 1.
About Guardant Health (NASDAQ:GH)
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
